Treatment of competition between complete fusion and quasifission in collisions of heavy nuclei

A model of competition between complete fusion and quasifission channels in fusion of two massive nuclei is extended to include the influence of dissipative effects on the dynamics of nuclear fusion. By using the multidimensional Kramers-type stationary solution of the Fokker-Planck equation, the fusion rate through the inner fusion barrier in mass asymmetry is studied. Fusion probabilities in symmetric 90Zr+90Zr, 100Mo+100Mo, 110Pd+110Pd, 136Xe+136Xe, almost symmetric 86Kr+136Xe and 110Pd+136Xe reactions are calculated. An estimation of the fusion probabilities is given for asymmetrical 62Ni+208Pb, 70Zn+208Pb, 82Se+208Pb, and 48Ca+244Pu reactions used for the synthesis of new superheavy elements.Comment: 29 pages, LaTeX, including 7 postscript figures, to appear in Nucl. Phys.

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Chronic obstructive pulmonary disease and sudden cardiac death: The Rotterdam study

Published on behalf of the European Society of Cardiology. All rights reserved